Arcus Biosciences, Inc. (RCUS) Gross Margin
- Gross margin · 12 months: Value (m); Formula and calculation Gross profit / revenue. Period ending 2026-06-30..
Gross margin
Overview →Financial period ending 2026-06-30; current quote (m). Amounts retain their stated periods and units.
| Metric | Value | Formula and calculation |
|---|---|---|
| Gross margin · 12 months | (m) | Gross profit / revenue. Period ending 2026-06-30. Calculation unavailable: missing inputs remain (m). |
Calculation inputs
| Input | Amount with unit | Raw financial data |
|---|---|---|
| Gross profit | (m) | |
| Revenue | 57.00M USD | Revenue from Contract with Customer, Excluding Assessed Tax |
| Cost of products and services | (m) |
Calculated history
Changes compare with the next older row (previous quarter), unless explicitly labeled otherwise. Rolling 12-month growth compares two successive quarter-end rolling totals; it is not year-over-year growth.
| Period ending | Gross profit (USD) | Revenue (USD) | Cost of products and services (USD) | Gross margin |
|---|---|---|---|---|
| 2026-06-30 | (m) | $57.00M | (m) | (m) |
| 2026-03-31 | (m) | $32.00M | (m) | (m) |
| 2025-12-31 | (m) | $33.00M | (m) | (m) |
| 2025-09-30 | (m) | $45.00M | (m) | (m) |
| 2025-06-30 | (m) | $46.00M | (m) | (m) |
| 2025-03-31 | (m) | $49.00M | (m) | (m) |
| 2024-12-31 | (m) | $51.00M | (m) | (m) |
| 2024-09-30 | (m) | $263.00M | (m) | (m) |
| 2024-06-30 | (m) | $247.00M | (m) | (m) |
| 2024-03-31 | (m) | $237.00M | (m) | (m) |
| 2023-12-31 | (m) | $117.00M | (m) | (m) |
| 2023-09-30 | (m) | $120.00M | (m) | (m) |
| 2023-06-30 | (m) | $121.00M | (m) | (m) |
| 2023-03-31 | (m) | $119.00M | (m) | (m) |
| 2022-12-31 | (m) | $112.00M | (m) | (m) |
| 2022-09-30 | (m) | $432.84M | (m) | (m) |
| 2022-06-30 | (m) | $408.72M | (m) | (m) |
| 2022-03-31 | (m) | $391.43M | (m) | (m) |
| 2021-12-31 | (m) | $382.88M | (m) | (m) |
| 2021-09-30 | (m) | $37.87M | (m) | (m) |
| 2021-06-30 | (m) | $92.94M | (m) | (m) |
| 2021-03-31 | (m) | $85.23M | (m) | (m) |
| 2020-12-31 | (m) | $77.52M | (m) | (m) |
| 2020-09-30 | (m) | $77.78M | (m) | (m) |
| 2020-06-30 | (m) | $15.00M | (m) | (m) |
| 2020-03-31 | (m) | $15.00M | (m) | (m) |
| 2019-12-31 | (m) | $15.00M | (m) | (m) |
| 2019-09-30 | (m) | $6.81M | (m) | (m) |
| 2019-06-30 | (m) | $9.35M | (m) | (m) |
| 2019-03-31 | (m) | $8.85M | (m) | (m) |
| 2018-12-31 | (m) | $8.35M | (m) | (m) |
| 2018-09-30 | (m) | (m) | (m) | (m) |
| 2018-06-30 | (m) | (m) | (m) | (m) |
| 2018-03-31 | (m) | (m) | (m) | (m) |
| 2017-12-31 | (m) | $1.41M | (m) | (m) |
| 2017-09-30 | (m) | (m) | (m) | (m) |
(m) means missing inputs. Historical market-based ratios use the saved close on or immediately before period ending and that period’s reported shares; current quotes are not substituted. Five-year projections repeat historical CAGR, not analyst forecasts.
Similar stocks
| Stock Name | Country | Market Cap | PE Ratio |
|---|---|---|---|
| Dyne Therapeutics, Inc. (DYN) | United States | $3.084B | -7.09 |
| Arcutis Biotherapeutics, Inc. (ARQT) | United States | $3.303B | 115.47 |
| Enliven Therapeutics, Inc. (ELVN) | United States | $3.307B | -35.07 |
| Amylyx Pharmaceuticals, Inc. (AMLX) | United States | $3.361B | -13.15 |
| IDEAYA Biosciences, Inc. (IDYA) | United States | $3.540B | -20.52 |
| Organon & Co. (OGN) | United States | $3.603B | 17.03 |
| PRECIGEN, INC. (PGEN) | United States | $2.757B | -12.94 |
| NewAmsterdam Pharma Co N.V. (NAMS) | $2.719B | -15.37 | |
| Xenon Pharmaceuticals Inc. (XENE) | $3.684B | -14.27 | |
| MBX Biosciences, Inc. (MBX) | United States | $2.664B | -25.36 |